Abstract
The clinical application of stem cells continues to fascinate the scientific and clinical communities. Despite the controversies surrounding this field, it is clear that stem cells have revolutionized regenerative medicine. Cell therapy is a progressively growing field that is moving fast from preclinical model development to clinical application. In this regard, outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy that deals with unmet medical treatment for several disorders with no therapeutic alternatives. The application of stem cells in regenerative medicine is addressing a wide range of clinical conditions using various types of stem cells. Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multi-differentiation, as well as by their anti-inflammatory, anti-proliferative, immunomodulatory, trophic, and pro-angiogenic properties. Various diseases have been successfully treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress or have concluded satisfactorily. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of other medical and physiological conditions on MSCs is important for assuring the feasibility, safety, and efficacy of cell-based therapies. This chapter will update and discuss the state of the art in MSCs’ cell-based therapies and provide relevant information regarding factors to consider for the clinical application of MSCs.
Abbreviations
- Ad-MSCs:
-
Adipose tissue-derived MSCs
- AGEs:
-
Advanced glycation end products
- ATMPs:
-
Advanced therapy medicinal products
- bFGF:
-
Basic fibroblast growth factor
- BM-MSCs:
-
Bone marrow-derived MSCs
- CAFs:
-
Cancer-associated fibroblasts
- Cas9:
-
CRISPR-associated protein 9
- CCL:
-
Chemokine (C-C motif) ligand
- CFU-F:
-
Colony-forming unit fibroblast
- CRISPR:
-
Clustered regularly interspaced short palindromic repeats
- CXCL12:
-
C-X-C motif chemokine 12 (or SDF1)
- Dkk-1:
-
Dickkopf-1
- ECs:
-
Endothelial cells
- EMA:
-
European Medicines Agency
- ESCs:
-
Embryonic stem cells
- EVs:
-
Extracellular vesicles
- FBS:
-
Fetal bovine serum
- FDA:
-
Food and Drug Administration
- GM-CSF:
-
Granulocyte-macrophage colony-stimulating factor
- GMP:
-
Good manufacturing practice
- GPS:
-
Glycotransferase-programmed stereo substitution
- GVHD:
-
Graft-versus-host diseases
- GVL:
-
Graft-versus-leukemia
- HCELL:
-
Hematopoietic cell E-selectin/L-selectin ligand
- HGF:
-
Hepatocyte growth factor
- HLA-DR:
-
Human leukocyte antigen-DR isotype
- HLA-G5:
-
Human leukocyte antigen-G5
- HSCT:
-
Hematopoietic stem cell transplantation
- IBMIR:
-
Instant blood-mediated inflammatory reaction
- ICAM-2:
-
Intercellular adhesion molecule 2
- IDO:
-
Indoleamine-2,3-dioxygenase
- IFN-γ:
-
Interferon-gamma
- IGF-1:
-
Insulin-like growth factor 1
- IL:
-
Interleukin
- IL-1α:
-
Interleukin-1 alpha
- IL-1β:
-
Interleukin-1 beta
- iPSCs:
-
Induced pluripotent stem cells
- ISCT:
-
International Society for Cellular Therapy
- ITP:
-
Immune thrombocytopenic purpura
- LFA-3:
-
Lymphocyte function-associated antigen 3 (or CD58)
- MCP-1:
-
Monocyte chemoattractant protein 1
- MHC-HLA:
-
Major histocompatibility complex-human leukocyte antigen
- MMP-2:
-
Matrix metalloproteinase 2
- MSCs:
-
Mesenchymal stromal cells
- PAI-1:
-
Plasminogen activator inhibitor-1
- PDGF:
-
Platelet-derived growth factor
- PD-MSCs:
-
Placenta-derived MSCs
- PGE-2:
-
Prostaglandin-E2
- RA:
-
Rheumatoid arthritis
- SDF-1:
-
Stromal cell-derived factor 1
- SLE:
-
Systemic lupus erythematosus
- SSc:
-
Systemic sclerosis
- STC1:
-
Stanniocalcin-1
- TALENs:
-
Transcription activator nucleases
- TbRIII:
-
Type III TGF-β receptor
- TGF-β:
-
Transforming growth factor beta
- TNF-α:
-
Tumor necrosis factor alpha
- tPA:
-
Tissue plasminogen activator
- TRAIL:
-
TNF-related apoptosis-inducing ligand
- Trx1:
-
Thioredoxin-1
- TSG-6:
-
Tumor necrosis factor-stimulated gene-6
- UCB-MSCs:
-
Umbilical cord-derived MSCs
- VCAM-1:
-
Vascular cell adhesion protein 1
- VEGF:
-
Vascular endothelial growth factor
- ZFNs:
-
Zinc finger nucleases
References
Acosta L, Hmadcha A, Escacena N, Pérez-Camacho I, de la Cuesta A, Ruiz-Salmeron R, Gauthier BR et al (2013) Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes 62(12):4266–4269. https://doi.org/10.2337/db13-0896
Afzal MR, Haider KH, Idris NM, Jiang S, Ahmed RPH, Ashraf M (2010) Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in infarcted heart via NF-кB signaling. Antioxid Redox Signal 12(6):693–702. https://doi.org/10.1089/ars.2009.2755
Akimoto K, Kimura K, Nagano M, Takano S, To'a Salazar G, Yamashita T, Ohneda O (2013) Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev 22(9):1370–1386. https://doi.org/10.1089/scd.2012.0486
Ancans J (2012) Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front Immunol 3:253. https://doi.org/10.3389/fimmu.2012.00253
Aoto K, Ito K, Aoki S (2018) Complex formation between platelet-derived growth factor receptor β and transforming growth factor β receptor regulates the differentiation of mesenchymal stem cells into cancer-associated fibroblasts. Oncotarget 9(75):34090–34102. https://doi.org/10.18632/oncotarget.26124
Bacigalupo A, Valle M, Podestà M, Pitto A, Zocchi E, De Flora A, Pozzi S et al (2005) T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 33(7):819–827. https://doi.org/10.1016/j.exphem.2005.05.006
Badenes SM, Fernandes TG, Cordeiro CS, Boucher S, Kuninger D, Vemuri MC, Diogo MM et al (2016) Defined essential 8™ medium and vitronectin efficiently support scalable xeno-free expansion of human induced pluripotent stem cells in stirred microcarrier culture systems. PLoS One 11(3):e0151264. https://doi.org/10.1371/journal.pone.0151264
Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH (2009) Human BM-derived MSCs induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57(11):1192–1203. https://doi.org/10.1002/glia.20841
Bajetto A, Pattarozzi A, Corsaro A, Barbieri F, Daga A, Bosio A, Gatti M et al (2017) Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front Cell Neurosci 11:312. https://doi.org/10.3389/fncel.2017.00312
Barcellos-de-Souza P, Comito G, Pons-Segura C, Taddei ML, Gori V, Becherucci V, Bambi F et al (2016) Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem Cells 34(10):2536–2547. https://doi.org/10.1002/stem.2412
Bari E, Perteghella S, Catenacci L, Sorlini M, Croce S, Mantelli M, Avanzini MA et al (2019) Freeze-dried and GMP-compliant pharmaceuticals containing exosomes for acellular mesenchymal stromal cell immunomodulant therapy. Nanomedicine (Lond) 14(6):753–765. https://doi.org/10.2217/nnm-2018-0240
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D et al (2013) Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. Cytotherapy 15(7):753–759. https://doi.org/10.1016/j.jcyt.2013.03.005
Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1):42–48. https://doi.org/10.1016/s0301-472x(01)00769-x
Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R et al (2007) Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Investig 30(9):RC26–RC30. https://doi.org/10.1007/BF03350807
Benvenuto F, Ferrari S, Gerdoni E, Gualandi F, Frassoni F, Pistoia V, Mancardi G et al (2007) Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25(7):1753–1760. https://doi.org/10.1634/stemcells.2007-0068
Bhoopathi P, Chetty C, Gogineni VR, Gujrati M, Dinh DH, Rao JS, Lakka SS (2011) MMP-2 mediates mesenchymal stem cell tropism towards medulloblastoma tumors. Gene Ther 18(7):692–701. https://doi.org/10.1038/gt.2011.14
Bianco P, Robey PG, Simmons PJ (2008) Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2(4):313–319. https://doi.org/10.1016/j.stem.2008.03.002
Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506–520. https://doi.org/10.1038/nrc1926
Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, Straube A (2007) Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neuro-Oncol 83(3):241–247. https://doi.org/10.1007/s11060-007-9332-4
Bortolotti F, Ukovich L, Razban V, Martinelli V, Ruozi G, Pelos B, Dore F et al (2015) In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure. Stem Cell Rep 4(3):332–339. https://doi.org/10.1016/j.stemcr.2015.01.001
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW et al (2007) Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110(4):1362–1369. https://doi.org/10.1182/blood-2006-12-063412
Bruder SP, Jaiswal N, Haynesworth SE (1997) Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 64(2):278–294. https://doi.org/10.1002/(sici)1097-4644(199702)64:2<278::aid-jcb11>3.0.co;2-f
Buccini S, Haider KH, Ahmed RPH, Jiang S, Ashraf M (2012) Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart. Basic Res Cardiol 107(6):301. https://doi.org/10.1007/s00395-012-0301-5
Burlacu A, Grigorescu G, Rosca AM, Preda MB, Simionescu M (2013) Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev 22(4):643–653. https://doi.org/10.1089/scd.2012.0273
Byrne SN, Knox MC, Halliday GM (2008) TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol 86(1):92–97. https://doi.org/10.1038/sj.icb.7100116
Cagliani J, Grande D, Molmenti EP, Miller EJ, Rilo HLR (2017) Immunomodulation by mesenchymal stromal cells and their clinical applications. J Stem Cell Regen Biol 3(2). https://doi.org/10.15436/2471-0598.17.022
Capilla-González V, López-Beas J, Escacena N, Aguilera Y, de la Cuesta A, Ruiz-Salmerón R, Martín F et al (2018) PDGF restores the defective phenotype of adipose-derived mesenchymal stromal cells from diabetic patients. Mol Ther 26(11):2696–2709. https://doi.org/10.1016/j.ymthe.2018.08.011
Caplan AI (2009) Why are MSCs therapeutic? New data: new insight. J Pathol 217(2):318–324. https://doi.org/10.1002/path.2469
Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076–1084. https://doi.org/10.1002/jcb.20886
Capra E, Beretta R, Parazzi V, Viganò M, Lazzari L, Baldi A, Giordano R (2012) Changes in the proteomic profile of adipose tissue-derived mesenchymal stem cells during passages. Proteome Sci 10(1):46. https://doi.org/10.1186/1477-5956-10-46
Carvalho JL, Braga VB, Melo MB, Campos AC, Oliveira MS, Gomes DA, Ferreira AJ et al (2013) Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med 17(5):617–625. https://doi.org/10.1111/jcmm.12036
Chao YH, Peng CT, Harn HJ, Chan CK, Wu KH (2010) Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol 89(7):715–723. https://doi.org/10.1007/s00277-009-0892-6
Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC (2010) A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 1(1):8. https://doi.org/10.1186/scrt8
Chen YC, Gonzalez ME, Burman B, Zhao X, Anwar T, Tran M, Medhora N et al (2019) Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer. Cell Rep 27(13):3916–3926.e5. https://doi.org/10.1016/j.celrep.2019.05.084
Cheng S, Nethi SK, Rathi S, Layek B, Prabha S (2019) Engineered mesenchymal stem cells for targeting solid tumors: therapeutic potential beyond regenerative therapy. J Pharmacol Exp Ther 370(2):231–241. https://doi.org/10.1124/jpet.119.259796
Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, Dolo V et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56(6):1994–2004. https://doi.org/10.1002/art.22698
Cobellis G, Silvestroni A, Lillo S, Sica G, Botti C, Maione C, Schiavone V et al (2008) Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 42(10):667–672. https://doi.org/10.1038/bmt.2008.228
Conget PA, Minguell JJ (1999) Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181(1):67–73. https://doi.org/10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO;2-C
Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, Gini B et al (2009) Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27(10):2624–2635. https://doi.org/10.1002/stem.194
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107(1):367–372. https://doi.org/10.1182/blood-2005-07-2657
Cramer C, Freisinger E, Jones RK, Slakey DP, Dupin CL, Newsome ER, Alt EU et al (2010) Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev 19(12):1875–1884. https://doi.org/10.1089/scd.2010.0009
Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313. https://doi.org/10.1016/j.stem.2008.07.003
De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, Benhaim P et al (2003) Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 89(2–3):267–270. https://doi.org/10.1016/s0165-2478(03)00108-1
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10):3838–3843. https://doi.org/10.1182/blood.v99.10.3838
Dias S, Shmelkov SV, Lam G, Rafii S (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99(7):2532–2540. https://doi.org/10.1182/blood.v99.7.2532
Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R (2001) CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 153(6):1277–1286. https://doi.org/10.1083/jcb.153.6.1277
Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noël D et al (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102(10):3837–3844. https://doi.org/10.1182/blood-2003-04-1193
Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P et al (2007) The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117(1):206–217. https://doi.org/10.1172/JCI29293
Duffy GP, Ahsan T, O’Brien T, Barry F, Nerem RM (2009) Bone marrow-derived mesenchymal stem cells promote angiogenic processes in a time- and dose-dependent manner in vitro. Tissue Eng Part A 15(9):2459–2470. https://doi.org/10.1089/ten.TEA.2008.0341
English K, Barry FP, Mahon BP (2008) Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 115(1):50–58. https://doi.org/10.1016/j.imlet.2007.10.002
Escacena N, Quesada-Hernández E, Capilla-González V, Soria B, Hmadcha A (2015) Bottlenecks in the efficient use of advanced therapy medicinal products based on mesenchymal stromal cells. Stem Cells Int 2015:895714. https://doi.org/10.1155/2015/895714
Fang B, Song YP, Liao LM, Han Q, Zhao RC (2006) Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 38(5):389–390. https://doi.org/10.1038/sj.bmt.1705457
Fathi E, Sanaat Z, Farahzadi R (2019) Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood Res 54(3):165–174. https://doi.org/10.5045/br.2019.54.3.165
Faulkner J, Jiang P, Farris D, Walker R, Dai Z (2020) CRISPR/CAS9-mediated knockout of Abi1 inhibits p185Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways. J Hematol Oncol 13(1):34. https://doi.org/10.1186/s13045-020-00867-5
Fazekasova H, Lechler R, Langford K, Lombardi G (2011) Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. J Tissue Eng Regen Med 5(9):684–694. https://doi.org/10.1002/term.362
Galiè M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, Krampera M et al (2008) Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 27(18):2542–2551. https://doi.org/10.1038/sj.onc.1210920
Gálvez P, Clares B, Bermejo M, Hmadcha A, Soria B (2014) Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells Dev 23(10):1074–1083. https://doi.org/10.1089/scd.2013.0625
Gálvez P, Clares B, Hmadcha A, Ruiz A, Soria B (2013) Development of a cell-based medicinal product: regulatory structures in the European Union. Br Med Bull 105:85–105. https://doi.org/10.1093/bmb/lds036
Ganta C, Chiyo D, Ayuzawa R, Rachakatla R, Pyle M, Andrews G, Weiss M, Tamura M, Troyer D et al (2009) Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res 69(5):1815–1820. https://doi.org/10.1158/0008-5472.CAN-08-2750
Gao P, Ding Q, Wu Z, Jiang H, Fang Z (2010) Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290(2):157–166. https://doi.org/10.1016/j.canlet.2009.08.031
Gao H, Priebe W, Glod J, Banerjee D (2009) Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells 27(4):857–865. https://doi.org/10.1002/stem.23
García-Bernal D, García-Arranz M, Yáñez RM, Hervás-Salcedo R, Cortés A, Fernández-García M, Hernando-Rodríguez M et al (2021) The current status of mesenchymal stromal cells: controversies, unresolved issues and some promising solutions to improve their therapeutic efficacy. Front Cell Dev Biol 9:650664. https://doi.org/10.3389/fcell.2021.650664
García-Bernal D, García-Arranz M, García-Guillén AI, García-Hernández AM, Blanquer M, García-Olmo D, Sackstein R et al (2020) Exofucosylation of adipose mesenchymal stromal cells alters their secretome profile. Front Cell Dev Biol 8:584074. https://doi.org/10.3389/fcell.2020.584074
George MJ, Prabhakara K, Toledano-Furman NE, Wang YW, Gill BS, Wade CE, Olson SD et al (2018) Clinical cellular therapeutics accelerate clot formation. Stem Cells Transl Med 7(10):731–739. https://doi.org/10.1002/sctm.18-0015
Gerace D, Martiniello-Wilks R, Nassif NT, Lal S, Steptoe R, Simpson AM (2017) CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Res Ther 8(1):62. https://doi.org/10.1186/s13287-017-0511-8
Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7):2821–2827. https://doi.org/10.1182/blood-2004-09-3696
Golchin A, Shams F, Karami F (2020) Advancing mesenchymal stem cell therapy with CRISPR/Cas9 for clinical trial studies. Adv Exp Med Biol 1247:89–100. https://doi.org/10.1007/5584_2019_459
González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60(4):1006–1019. https://doi.org/10.1002/art.24405
Gottipamula S, Muttigi MS, Kolkundkar U, Seetharam RN (2013) Serum-free media for the production of human mesenchymal stromal cells: a review. Cell Prolif 46(6):608–627. https://doi.org/10.1111/cpr.12063
Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E (2007) Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12(4):313–327. https://doi.org/10.1016/j.ccr.2007.08.020
Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, Ji X et al (2017) Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev 31(3):247–259. https://doi.org/10.1101/gad.294348.116
Gupta NK, Armstrong EJ, Parikh SA (2014) The current state of stem cell therapy for peripheral artery disease. Curr Cardiol Rep 16(2):447. https://doi.org/10.1007/s11886-013-0447-2
Haider KH, Ashraf M (2012) Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci 111:323–356. https://doi.org/10.1016/B978-0-12-398459-3.00015-0
Haider KH, Aramini B (2020) Mircrining the injured heart with stem cell-derived exosomes: an emerging strategy of cell-free therapy. Stem Cell Res Ther 11(1):23. https://doi.org/10.1186/s13287-019-1548-7
Haider KH, Aslam M (2018) Cell-free therapy with stem cell secretions: protection, repair and regeneration of the injured myocardium. In: Haider KH, Aziz S (eds) Stem cells: from hype to real hope. Medicine & Life Sciences, DE GRUYTER, Berlin. (Published, 2018). https://doi.org/10.1515/9783110642438
Haider KH, Jiang S, Niagara MI, Ashraf M (2008) IGF-I over expressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1α/CXCR4 signaling to promote myocardial repair. Circulation Res 103:1300–1308. https://doi.org/10.1161/CIRCRESAHA.108.186742
Han J, Zhao J, Xu J, Wen Y (2014) Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med 8(4):1330–1334. https://doi.org/10.3892/etm.2014.1918
Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF et al (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res 61(3):1162–1170
Hashi CK, Zhu Y, Yang GY, Young WL, Hsiao BS, Wang K, Chu B et al (2007) Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts. Proc Natl Acad Sci U S A 104(29):11915–11920. https://doi.org/10.1073/pnas.0704581104
Herberts CA, Kwa MS, Hermsen HP (2011) Risk factors in the development of stem cell therapy. J Transl Med 9:29. https://doi.org/10.1186/1479-5876-9-29
Hmadcha A, Dominguez-Bendala J, Wakeman J, Arredouani M, Soria B (2009) The immune boundaries for stem cell based therapies: problems and prospective solutions. J Cell Mol Med 13(8A):1464–1475. https://doi.org/10.1111/j.1582-4934.2009.00837.x
Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-González V (2020) Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol 8:43. https://doi.org/10.3389/fbioe.2020.00043
Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, Lam PY (2013) Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 31(1):146–155. https://doi.org/10.1002/stem.1247
Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE (2006) Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24(4):1030–1041. https://doi.org/10.1634/stemcells.2005-0319
Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L et al (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 99(13):8932–8937. https://doi.org/10.1073/pnas.132252399
Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ et al (2005) Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7(5):393–395. https://doi.org/10.1080/14653240500319234
Hunt JS, Petroff MG, McIntire RH, Ober C (2005) HLA-G and immune tolerance in pregnancy. FASEB J 19(7):681–693. https://doi.org/10.1096/fj.04-2078rev
Iglesias-López C, Agustí A, Obach M, Vallano A (2019) Regulatory framework for advanced therapy medicinal products in Europe and United States. Front Pharmacol 10:921. https://doi.org/10.3389/fphar.2019.00921
Ishikawa I, Sawada R, Kato Y, Tsuji K, Shao J, Yamada T, Kato R et al (2009) Effectivity of the novel serum-free medium STK2 for proliferating human mesenchymal stem cells. Yakugaku Zasshi 129(3):381–384. Japanese. https://doi.org/10.1248/yakushi.129.381
Jayme DW, Smith SR (2000) Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture. Cytotechnology 33(1–3):27–36. https://doi.org/10.1023/A:1008133717035
Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y et al (2011) Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med 5(1):94–100. https://doi.org/10.1007/s11684-011-0116-z
Jiang S, Haider KH, Niagara MI, Salim A, Ashraf M (2006) Supportive interaction between cell survival signaling and angio-competent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circulation Res 99:776–784. https://doi.org/10.1161/01.RES.0000244687.97719.4f
Jiang S, Haider KH, Niagara MI, Lu G, Ashraf M (2008) Stable therapeutic effects of mesenchymal stem cell based multiple gene delivery for cardiac repair. Cardiovasc Res 77(3):525–533. https://doi.org/10.1093/cvr/cvm077
Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, Krishnappa S et al (2011) Adipose tissue derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor derived factors. Cell Oncol (Dordr) 34(1):55–67. https://doi.org/10.1007/s13402-011-0012-1
Julier Z, Park AJ, Briquez PS, Martino MM (2017) Promoting tissue regeneration by modulating the immune system. Acta Biomater 53:13–28. https://doi.org/10.1016/j.actbio.2017.01.056
Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P et al (2010) Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59(12):3139–3147. https://doi.org/10.2337/db10-0542
Kalimuthu S, Oh JM, Gangadaran P, Zhu L, Lee HW, Rajendran RL, Baek SH et al (2017) In vivo tracking of chemokine receptor CXCR4-engineered mesenchymal stem cell migration by optical molecular imaging. Stem Cells Int 2017:8085637. https://doi.org/10.1155/2017/8085637
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16(9):582–598. https://doi.org/10.1038/nrc.2016.73
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557–563. https://doi.org/10.1038/nature06188
Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM et al (2008) Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 67(6):741–749. https://doi.org/10.1136/ard.2007.076174
Kern S, Eichler H, Stoeve J, Klüter H, Bieback K (2006) Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24(5):1294–1301. https://doi.org/10.1634/stemcells.2005-0342
Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT et al (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 203(5):1235–1247. https://doi.org/10.1084/jem.20051921
Kim CK, Haider KH, Lim SJ (2001) Gene medicine: a new field of molecular medicine. Arch Pharmacol Res 24(1):1–15. https://doi.org/10.1007/BF02976486
Kim DS, Jang IK, Lee MW, Ko YJ, Lee DH, Lee JW, Sung KW et al (2018) Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine 28:261–273. https://doi.org/10.1016/j.ebiom.2018.01.002
Kim HW, Malik F, Durrani S, Ashraf M, Jiang S, Haider KH (2012a) Concomitant Activation of miR-107/PDCD10 and Hypoxamir-210/Casp8ap2 and Their Role in Cytoprotection During Ischemic Preconditioning of Stem Cells. Antioxidant Redox Signal 17(8):1053–1065. https://doi.org/10.1089/ars.2012.4518
Kim HW, Ashraf M, Jiang S, Haider KH (2012b) Stem cell based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of the infarcted heart function. J Mol Med 90(9):997–1010. https://doi.org/10.1007/s00109-012-0920-1
Kim JS, Kim JG, Moon MY, Jeon CY, Won HY, Kim HJ, Jeon YJ et al (2006) Transforming growth factor-beta1 regulates macrophage migration via RhoA. Blood 108(6):1821–1829. https://doi.org/10.1182/blood-2005-10-009191
Kinzebach S, Bieback K (2013) Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotechnol 129:33–57. https://doi.org/10.1007/10_2012_134
Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18(2):307–316. https://doi.org/10.1200/JCO.2000.18.2.307
Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13(3):159–175. https://doi.org/10.1038/nri3399
König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E et al (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11(2):258–265. https://doi.org/10.1038/sj.leu.2400556
Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V et al (2006) Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2):386–398. https://doi.org/10.1634/stemcells.2005-0008
Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L, MSC Committee of the International Society for Cellular Therapy (ISCT) (2013) Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15(9):1054–1061. https://doi.org/10.1016/j.jcyt.2013.02.010
Krampera M (2011) Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia 25(9):1408–1414. https://doi.org/10.1038/leu.2011.108
Krampera M, Sartoris S, Liotta F, Pasini A, Angeli R, Cosmi L, Andreini A et al (2007) Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev 16(5):797–810. https://doi.org/10.1089/scd.2007.0024
Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T et al (2005) Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20(9):1647–1658. https://doi.org/10.1359/JBMR.050514
Kunter U, Rong S, Boor P, Eitner F, Müller-Newen G, Djuric Z, van Roeyen CR et al (2007) Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 18(6):1754–1764. https://doi.org/10.1681/ASN.2007010044
Lai VK, Afzal MR, Ashraf M, Jiang S, Haider KH (2012a) Non-hypoxic stabilization of Hif-1α during coordinated interaction between Akt and angiopoietin-1 enhances endothelial commitment of bone marrow stem cells. J Mol Med 90(6):719–730. https://doi.org/10.1007/s00109-011-0852-1
Lai VK, Ashraf M, Jiang S, Haider KH (2012b) MicroRNA-143 is critical regulator of cell cycle activity in stem cells with co-overexpression of Akt and angiopoietin-1 via transcriptional regulation of Erk5/Cyclin D1 signaling. Cell Cycle 11(4):767–677. https://doi.org/10.4161/cc.11.4.19211
Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ et al (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11(5):389–398. https://doi.org/10.1016/j.bbmt.2005.02.001
Le Blanc K (2003) Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5(6):485–489. https://doi.org/10.1080/14653240310003611
Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441. https://doi.org/10.1016/S0140-6736(04)16104-7
Lee JM, Jung J, Lee HJ, Jeong SJ, Cho KJ, Hwang SG, Kim GJ (2012a) Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. Int Immunopharmacol 13(2):219–224. https://doi.org/10.1016/j.intimp.2012.03.024
Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 103(46):17438–17443. https://doi.org/10.1073/pnas.0608249103
Lee T (2010) Host tissue response in stem cell therapy. World J Stem Cells 2(4):61–66. https://doi.org/10.4252/wjsc.v2.i4.61
Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, Sun B et al (2009) Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 42(6):711–720. https://doi.org/10.1111/j.1365-2184.2009.00633.x
Lee RH, Yoon N, Reneau JC, Prockop DJ (2012b) Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell Stem Cell 11(6):825–835. https://doi.org/10.1016/j.stem.2012.10.001
Li GC, Zhang HW, Zhao QC, Sun LI, Yang JJ, Hong L, Feng F et al (2016) Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1. Oncol Lett 11(2):1089–1094. https://doi.org/10.3892/ol.2015.3997
Li B, Fu J, Chen P, Zhuang W (2010) Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res 41(8):623–633. https://doi.org/10.1016/j.arcmed.2010.11.008
Li W, Zhou Y, Yang J, Zhang X, Zhang H, Zhang T, Zhao S et al (2015) Gastric cancer-derived mesenchymal stem cells prompt gastric cancer progression through secretion of interleukin-8. J Exp Clin Cancer Res 34(1):52. https://doi.org/10.1186/s13046-015-0172-3
Li Y, Zhang D, Xu L, Dong L, Zheng J, Lin Y, Huang J et al (2019) Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. Cell Mol Immunol 16(12):908–920. https://doi.org/10.1038/s41423-019-0204-6
Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y et al (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69(8):1423–1429. https://doi.org/10.1136/ard.2009.123463
Liao L, Shi B, Chang H, Su X, Zhang L, Bi C, Shuai Y et al (2017) Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics 7(1):106–116. https://doi.org/10.7150/thno.16911
Lo B, Parham L (2009) Ethical issues in stem cell research. Endocr Rev 30(3):204–213. https://doi.org/10.1210/er.2008-0031
López-Lucas MD, Pachón-Peña G, García-Hernández AM, Parrado A, Sánchez-Salinas D, García-Bernal D, Algueró MDC et al (2018) Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications. Cytotherapy 20(9):1110–1123. https://doi.org/10.1016/j.jcyt.2018.07.001
Lourenco S, Teixeira VH, Kalber T, Jose RJ, Floto RA, Janes SM (2015) Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol 194(7):3463–3474. https://doi.org/10.4049/jimmunol.1402097
Lu G, Ashraf M, Haider KH (2012) Insulin-Like Growth Factor-1 Preconditioning Accentuates Intrinsic Survival Mechanism in Stem Cells to Resist Ischemic Injury by Orchestrating Protein Kinase Cα–Erk1/2 Activation. Antioxidant Red Signaling 16(3):217–227. https://doi.org/10.1089/ars.2011.4112
Lu G, Haider KH, Porollo A, Ashraf M (2010) Mitochondria specific transgenic overexpression of connexin-43 simulates preconditioning induced cytoprotection of stem cells. Cardiovasc Res 88:277–286. https://doi.org/10.1093/cvr/cvq293
Lu L, Chen G, Yang J, Ma Z, Yang Y, Hu Y, Lu Y et al (2019) Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway. Biomed Pharmacother 112:108625. https://doi.org/10.1016/j.biopha.2019.108625
Ma J, Liu N, Yi B, Zhang X, Gao BB, Zhang Y, Xu R et al (2015) Transplanted hUCB-MSCs migrated to the damaged area by SDF-1/CXCR4 signaling to promote functional recovery after traumatic brain injury in rats. Neurol Res 37(1):50–56. https://doi.org/10.1179/1743132814Y.0000000399
Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L et al (2005) Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90(4):516–525
Maltman DJ, Hardy SA, Przyborski SA (2011) Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem Int 59(3):347–356. https://doi.org/10.1016/j.neuint.2011.06.008
Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9(9):1195–1201. https://doi.org/10.1038/nm912
Mao F, Wu Y, Tang X, Kang J, Zhang B, Yan Y, Qian H et al (2017) Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice. Biomed Res Int 2017:5356760. https://doi.org/10.1155/2017/5356760
Mastri M, Shah Z, McLaughlin T, Greene CJ, Baum L, Suzuki G, Lee T (2012) Activation of toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol 303(10):C1021–C1033. https://doi.org/10.1152/ajpcell.00191.2012
Mazzanti B, Aldinucci A, Biagioli T, Barilaro A, Urbani S, Dal Pozzo S, Amato MP et al (2008) Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol 199(1–2):142–150. https://doi.org/10.1016/j.jneuroim.2008.05.006
McAuley DF, Curley GF, Hamid UI, Laffey JG, Abbott J, McKenna DH, Fang X et al (2014) Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 306(9):L809–L815. https://doi.org/10.1152/ajplung.00358.2013
Mead B, Chamling X, Zack DJ, Ahmed Z, Tomarev S (2020) TNFα-mediated priming of mesenchymal stem cells enhances their neuroprotective effect on retinal ganglion cells. Invest Ophthalmol Vis Sci 61(2):6. https://doi.org/10.1167/iovs.61.2.6
Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ (2007) Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 4(9):e269. https://doi.org/10.1371/journal.pmed.0040269
Meirelles Lda S, Fontes AM, Covas DT, Caplan AI (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20(5–6):419–427. https://doi.org/10.1016/j.cytogfr.2009.10.002
Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H (2013) Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2(6):455–463. https://doi.org/10.5966/sctm.2012-0184
Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1):23–36. https://doi.org/10.1182/blood-2013-01-306647
Minteer DM, Young MT, Lin YC, Over PJ, Rubin JP, Gerlach JC, Marra KG (2015) Analysis of type II diabetes mellitus adipose-derived stem cells for tissue engineering applications. J Tissue Eng 6:2041731415579215. https://doi.org/10.1177/2041731415579215
Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S et al (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68(11):4331–4339. https://doi.org/10.1158/0008-5472.CAN-08-0943
Miwa H, Era T (2018) Tracing the destiny of mesenchymal stem cells from embryo to adult bone marrow and white adipose tissue via Pdgfrα expression. Development 145(2):dev155879. https://doi.org/10.1242/dev.155879
Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25(1):1–6. https://doi.org/10.1038/leu.2010.224
Molavi B, Zafarghandi MR, Aminizadeh E, Hosseini SE, Mirzayi H, Arab L, Baharvand H et al (2016) Safety and efficacy of repeated bone marrow mononuclear cell therapy in patients with critical limb ischemia in a pilot randomized controlled trial. Arch Iran Med 19(6):388–396
Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringdén O, Volk HD, Geissler S et al (2019) Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med 25(2):149–163. https://doi.org/10.1016/j.molmed.2018.12.006
Moll G, Hult A, von Bahr L, Alm JJ, Heldring N, Hamad OA, Stenbeck-Funke L et al (2014) Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS One 9(1):e85040. https://doi.org/10.1371/journal.pone.0085040
Moll G, Jitschin R, von Bahr L, Rasmusson-Duprez I, Sundberg B, Lönnies L, Elgue G et al (2011) Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One 6(7):e21703. https://doi.org/10.1371/journal.pone.0021703
Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P (2020) MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front Immunol 11:1091. https://doi.org/10.3389/fimmu.2020.01091
Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, Hamad OA et al (2012) Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells 30(7):1565–1574. https://doi.org/10.1002/stem.1111
Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D et al (2010) Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources. Cell Immunol 264(2):171–179. https://doi.org/10.1016/j.cellimm.2010.06.006
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J et al (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65(8):3307–3318. https://doi.org/10.1158/0008-5472.CAN-04-1874
Neuss S, Schneider RK, Tietze L, Knüchel R, Jahnen-Dechent W (2010) Secretion of fibrinolytic enzymes facilitates human mesenchymal stem cell invasion into fibrin clots. Cells Tissues Organs 191(1):36–46. https://doi.org/10.1159/000215579
Nie Y, Lau C, Lie A, Chan G, Mok M (2010) Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 19(7):850–859. https://doi.org/10.1177/0961203309361482
Nilsson B, Teramura Y, Ekdahl KN (2014) The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies. Mol Immunol 61(2):185–190. https://doi.org/10.1016/j.molimm.2014.06.009
Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z et al (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22(3):593–599. https://doi.org/10.1038/sj.leu.2405090
Noronha NC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha JLM, Covas DT, Swiech K et al (2019) Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther 10(1):131. https://doi.org/10.1186/s13287-019-1224-y
Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J (2009) Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 113(18):4197–4205. https://doi.org/10.1182/blood-2008-09-176198
Pachón-Peña G, Donnelly C, Ruiz-Cañada C, Katz A, Fernández-Veledo S, Vendrell J, Sackstein R (2017) A glycovariant of human CD44 is characteristically expressed on human mesenchymal stem cells. Stem Cells 35(4):1080–1092. https://doi.org/10.1002/stem.2549
Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT, Eliopoulos GD (2002) Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 99(5):1610–1619. https://doi.org/10.1182/blood.v99.5.1610
Pérez-Simón JA, Tabera S, Sarasquete ME, Díez-Campelo M, Canchado J, Sánchez-Abarca LI, Blanco B et al (2009) Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 11(6):698–705. https://doi.org/10.3109/14653240903051558
Pérez LM, de Lucas B, Gálvez BG (2018) Unhealthy stem cells: when health conditions upset stem cell properties. Cell Physiol Biochem 46(5):1999–2016. https://doi.org/10.1159/000489440
Petrie RJ, Doyle AD, Yamada KM (2009) Random versus directionally persistent cell migration. Nat Rev Mol Cell Biol 10(8):538–549. https://doi.org/10.1038/nrm2729
Phinney DG (2012) Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 113(9):2806–2812. https://doi.org/10.1002/jcb.24166
Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ (1999) Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 75(3):424–436
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147. https://doi.org/10.1126/science.284.5411.143
Potapova IA, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, Doronin SV (2007) Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 25(7):1761–1768. https://doi.org/10.1634/stemcells.2007-0022
Powell D, Lou M, Barros Becker F, Huttenlocher A (2018) Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo. Sci Rep 8(1):13285. https://doi.org/10.1038/s41598-018-31675-0
Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309):71–74. https://doi.org/10.1126/science.276.5309.71
Prockop DJ, Oh JY (2012) Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 20(1):14–20. https://doi.org/10.1038/mt.2011.211
Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD (2008a) Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 269(1):67–77. https://doi.org/10.1016/j.canlet.2008.04.032
Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L et al (2008b) Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18(4):500–507. https://doi.org/10.1038/cr.2008.40
Rafei M, Birman E, Forner K, Galipeau J (2009) Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 17(10):1799–1803. https://doi.org/10.1038/mt.2009.157
Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26(1):151–162. https://doi.org/10.1634/stemcells.2007-0416
Ramos-Zúñiga R, González-Pérez O, Macías-Ornelas A, Capilla-González V, Quiñones-Hinojosa A (2012) Ethical implications in the use of embryonic and adult neural stem cells. Stem Cells Int 2012:470949. https://doi.org/10.1155/2012/470949
Rani S, Ryan AE, Griffin MD, Ritter T (2015) Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 23(5):812–823. https://doi.org/10.1038/mt.2015.44
Relation T, Yi T, Guess AJ, La Perle K, Otsuru S, Hasgur S, Dominici M et al (2018) Intratumoral delivery of interferonγ-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo. Stem Cells 36(6):915–924. https://doi.org/10.1002/stem.2801
Ren G, Su J, Zhang L, Zhao X, Ling W, L’huillie A, Zhang J et al (2009) Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27(8):1954–1962. https://doi.org/10.1002/stem.118
Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W, Roberts AI et al (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184(5):2321–2328. https://doi.org/10.4049/jimmunol.0902023
Rennert RC, Sorkin M, Januszyk M, Duscher D, Kosaraju R, Chung MT, Lennon J et al (2014) Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem Cell Res Ther 5(3):79. https://doi.org/10.1186/scrt468
Ricciardi M, Malpeli G, Bifari F, Bassi G, Pacelli L, Nwabo Kamdje AH, Chilosi M et al (2012) Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. PLoS One 7(5):e35639. https://doi.org/10.1371/journal.pone.0035639
Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, Marschall HU et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10):1390–1397. https://doi.org/10.1097/01.tp.0000214462.63943.14
Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C et al (2007) Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 101(1):135–146. https://doi.org/10.1002/jcb.21172
Rivera FJ, de la Fuente AG, Zhao C, Silva ME, Gonzalez GA, Wodnar R, Feichtner M et al (2019) Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination. Glia 67(8):1510–1525. https://doi.org/10.1002/glia.23624
Røsland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J et al (2009) Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 69(13):5331–5339. https://doi.org/10.1158/0008-5472.CAN-08-4630
Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R (2008) Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14(2):181–187. https://doi.org/10.1038/nm1703
Sakaguchi Y, Sekiya I, Yagishita K, Muneta T (2005) Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 52(8):2521–2529. https://doi.org/10.1002/art.21212
Sensebé L, Gadelorge M, Fleury-Cappellesso S (2013) Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther 4(3):66. https://doi.org/10.1186/scrt217
Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC (2011) The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 18(5):488–495. https://doi.org/10.1038/gt.2010.170
Shabbir A, Zisa D, Suzuki G, Lee T (2009) Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 296(6):H1888–H1897. https://doi.org/10.1152/ajpheart.00186.2009
Shin L, Peterson DA (2012) Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med 1(2):125–135. https://doi.org/10.5966/sctm.2012-0031
Shrestha C, Zhao L, Chen K, He H, Mo Z (2013) Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media. Int J Endocrinol 2013:592454. https://doi.org/10.1155/2013/592454
Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT (2014) Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev Rep 10(3):351–375. https://doi.org/10.1007/s12015-014-9495-2
Song JY, Kang HJ, Ju HM, Park A, Park H, Hong JS, Kim CJ et al (2019) Umbilical cord-derived mesenchymal stem cell extracts ameliorate atopic dermatitis in mice by reducing the T cell responses. Sci Rep 9(1):6623. https://doi.org/10.1038/s41598-019-42964-7
Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, Belmonte N et al (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106(2):419–427. https://doi.org/10.1182/blood-2004-09-3507
Soria-Juan B, Escacena N, Capilla-González V, Aguilera Y, Llanos L, Tejedo JR, Bedoya FJ et al (2019) Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus. Front Immunol 10:1151. https://doi.org/10.3389/fimmu.2019.01151
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1):74–85. https://doi.org/10.1634/stemcells.2004-0359
Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113(26):6576–6583. https://doi.org/10.1182/blood-2009-02-203943
Stagg J, Pommey S, Eliopoulos N, Galipeau J (2006) Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107(6):2570–2577. https://doi.org/10.1182/blood-2005-07-2793
Stenderup K, Justesen J, Clausen C, Kassem M (2003) Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33(6):919–926. https://doi.org/10.1016/j.bone.2003.07.005
Sudres M, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, Lataillade JJ et al (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176(12):7761–7767. https://doi.org/10.4049/jimmunol.176.12.7761
Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM (2007) Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16(2):121–128. https://doi.org/10.1177/0961203306075793
Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B et al (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62(8):2467–24675. https://doi.org/10.1002/art.27548
Suresh SC, Selvaraju V, Thirunavukkarasu M, Goldman JW, Husain A, Alexander Palesty J, Sanchez JA et al (2015) Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int J Cardiol 201:517–528. https://doi.org/10.1016/j.ijcard.2015.08.117
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7(1):94–100. https://doi.org/10.1038/83416
Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X et al (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307(11):1169–1177. https://doi.org/10.1001/jama.2012.316
Tan KL, Chia WC, How CW, Tor YS, Show PL, Looi QHD, Foo JB (2021) Benchtop isolation and characterisation of small extracellular vesicles from human mesenchymal stem cells. Mol Biotechnol. https://doi.org/10.1007/s12033-021-00339-2
Teraa M, Sprengers RW, Schutgens RE, Slaper-Cortenbach IC, van der Graaf Y, Algra A, van der Tweel I et al (2015) Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 131(10):851–860. https://doi.org/10.1161/CIRCULATIONAHA.114.012913
Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F (2007) Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 21(9):1992–1999. https://doi.org/10.1038/sj.leu.2404847
Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726–736. https://doi.org/10.1038/nri2395
Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J et al (2019) Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 21(10):1019–1024. https://doi.org/10.1016/j.jcyt.2019.08.002
von Einem JC, Guenther C, Volk HD, Grütz G, Hirsch D, Salat C, Stoetzer O et al (2019) Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: results from the phase 1/2 TREAT-ME-1 trial. Int J Cancer 145(6):1538–1546. https://doi.org/10.1002/ijc.32230
Von Lüttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, Djafarzadeh R et al (2005) Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev 14(3):329–336. https://doi.org/10.1089/scd.2005.14.329
Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B, Wei X et al (2018) Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. J Hematol Oncol 11(1):11. https://doi.org/10.1186/s13045-018-0554-z
Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK (2005) Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7(6):509–519. https://doi.org/10.1080/14653240500363216
Wang B, Wu SM, Wang T, Liu K, Zhang G, Zhang XQ, Yu JH et al (2012) Pre-treatment with bone marrow-derived mesenchymal stem cells inhibits systemic intravascular coagulation and attenuates organ dysfunction in lipopolysaccharide-induced disseminated intravascular coagulation rat model. Chin Med J 125(10):1753–1759
Wegmeyer H, Bröske AM, Leddin M, Kuentzer K, Nisslbeck AK, Hupfeld J, Wiechmann K et al (2013) Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev 22(19):2606–2618. https://doi.org/10.1089/scd.2013.0016
Wessman SJ, Levings RL (1999) Benefits and risks due to animal serum used in cell culture production. Dev Biol Stand 99:3–8
Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673–682. https://doi.org/10.1016/1074-7613(95)90057-8
Wobus M, List C, Dittrich T, Dhawan A, Duryagina R, Arabanian LS, Kast K et al (2015) Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. Int J Cancer 136(1):44–54. https://doi.org/10.1002/ijc.28960
Woodbury D, Reynolds K, Black IB (2002) Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 69(6):908–917. https://doi.org/10.1002/jnr.10365
Wynn RF, Hart CA, Corradi-Perini C, O’Neill L, Evans CA, Wraith JE, Fairbairn LJ et al (2004) A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104(9):2643–2645. https://doi.org/10.1182/blood-2004-02-0526
Xu WT, Bian ZY, Fan QM, Li G, Tang TT (2009) Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett 281(1):32–41. https://doi.org/10.1016/j.canlet.2009.02.022
Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA (2006) Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 24(11):2582–2591. https://doi.org/10.1634/stemcells.2006-0228
Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, Lee JE et al (2009) Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 259(2):150–156. https://doi.org/10.1016/j.cellimm.2009.06.010
Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D et al (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5):1755–1761. https://doi.org/10.1182/blood-2005-04-1496
Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, Mitchell JB et al (2005) Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 195(1):16–26. https://doi.org/10.1016/j.expneurol.2005.03.018
Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G (2013) Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 4(3):70. https://doi.org/10.1186/scrt221
Zhao Q, Gregory CA, Lee RH, Reger RL, Qin L, Hai B, Park MS et al (2015) MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci U S A 112(2):530–535. https://doi.org/10.1073/pnas.1423008112
Zhao ZG, Liang Y, Li K, Li WM, Li QB, Chen ZC, Zou P (2007) Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 16(4):637–648. https://doi.org/10.1089/scd.2007.0008
Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, Lai P (2021) Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol 14(1):24. https://doi.org/10.1186/s13045-021-01037-x
Zhu J, Liu Y, Chen C, Chen H, Huang J, Luo Y, Zhao K et al (2021) Cyasterone accelerates fracture healing by promoting MSCs migration and osteogenesis. J Orthop Translat 28:28–38. https://doi.org/10.1016/j.jot.2020.11.004
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Hmadcha, A., Soria, B., Tejedo, J.R., Bedoya, F.J., Sempere-Ortells, J.M., Smani, T. (2022). Considerations for Clinical Use of Mesenchymal Stromal Cells. In: Haider, K.H. (eds) Handbook of Stem Cell Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-16-6016-0_3-1
Download citation
DOI: https://doi.org/10.1007/978-981-16-6016-0_3-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-6016-0
Online ISBN: 978-981-16-6016-0
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences